image de fond

Publication about a new formulation for morphine sulfate

Atrux-Tallau et al. Pharmacokinetics of Morphine Sulfate Orodispersible Tablets and Bioequivalence with Immediate-Release Oral Morphine Sulfate Formulations. Clin Drug Investig (2022).

November 10, 2022

Decreasing moderate-to-severe pain using an opioid, a fine-tuning process

Morphine sulfate is a well-established first-line opioid used to treat moderate-to-severe pain. In adults and adolescents with cancer pain, the World Health Organization (WHO) recommends reducing pain to a level that allows patients to have an acceptable quality of life.

Determining the right dosage of morphine sulfate to be used requires evaluating the origin and type of pain, and choosing the drug formulation that will be the most effective. Oral immediate-release or modified-release tablets or capsules, oral solutions/suspensions, or parenteral forms of morphine sulfate are available at various dosages. The benefit of pain relief must be balanced against the risk of adverse effects and overdose, which may result in respiratory depression. The WHO, the European Society for Medical Oncology (ESMO), the Centers for Disease Control and Prevention (CDC) and the American Geriatrics Society (AGS) recommend using the least invasive route (i.e., oral), and the lowest dose possible for titration to the minimal effective opioid dose for managing pain relief.

A panel of morphine sulfate orodispersible tablets (1 à 30 mg)

The expertise of Santé Active Edition – Synergy Pharm